Why Alnylam's Best Quarter Ever Didn't Come With a Richer Valuation
2026 has marked a significant turning point in biotech capital markets, not just a small comeback.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Antipodes Partners Jacob Mitchell | 163,533 | $49,228,339 | +13% | 0.9% |
| 2. | Bronte Capital John Hempton | 35,384 | $10,651,646 | -5% | 1.14% |
| 3. | Motley Fool Asset Management Bryan Hinmon | 9,170 | $2,760,445 | -13% | 0.11% |
| 4. | 6,900 | $2,077,107 | +17% | 0.01% | |
| 5. | Fisher Asset Management Ken Fisher | 6,252 | $1,882,119 | +4% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.67 | 4 | $1,210.68 | 36 | 2024-10-17 | Filing | |
| $286.00 | 32 | $9,152.00 | 32 | 2024-08-29 | Filing | |
| $71.87 | 297,501 | $21,381,396.87 | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | $751,502.00 | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | $1,032,327.90 | 27,900 | 2016-10-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.65 | 17 | $5,145.05 | 1,582 | 2026-06-01 | Filing | |
| $300.72 | 495 | $148,856.40 | 1,599 | 2026-06-01 | Filing | |
| $299.87 | 1,222 | $366,441.14 | 2,094 | 2026-06-01 | Filing | |
| $298.91 | 1,175 | $351,219.25 | 3,316 | 2026-06-01 | Filing | |
| $297.71 | 921 | $274,190.91 | 4,491 | 2026-06-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,439,889 | $734,479,786 | 0.67% | |
| 2. | 492,071 | $148,128,276 | 0.02% | |
| 3. | 350,560 | $105,524,729 | 0.03% | |
| 4. | 325,379 | $97,948,840 | 0.06% | |
| 5. | 278,613 | $83,257,214 | 0.08% |
News See All
10 Best Growth Stocks With Highest Upside Potential
BlackRock says “Earnings strength is broadening” and points to a “new trend of upward revisions,” while also noting that “non-Mag 7 earnings power may be underappreciated.” In summary, the...
What Offers Alnylam Pharmaceuticals (ALNY) Sustained Long-Term Growth?
Brown Advisory, an investment management company, released its “Brown Large-Cap Growth Strategy” for the first-quarter 2026 investor letter. A copy of the letter is available to download here.
10 Best Fundamentally Strong Stocks to Buy for Long Term
On June 22, CNBC reported that the co-head of global investment strategy at JPMorgan Private Bank, Stephen Parker, on “Squawk Box,” commented that this year's stock market surge has been "entirely...
10 Most Promising Long-Term Stocks to Buy According to Analysts
On June 11, Emily Roland, Manulife John Hancock Investment Management, Co-Chief Investment Strategist, joined 'Squawk Box' on CNBC to describe the current market environment as a momentum freight train...
12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On
On May 27, Reuters reported that Biohub, a philanthropic venture formed by Meta CEO Mark Zuckerberg and Dr. Priscilla Chan, developed a global model of protein biology to speed up drug discovery.
10 Most Promising Healthcare Stocks According to Wall Street Analysts
The US healthcare sector has trailed the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
15 High-Growth Large-Cap Stocks to Invest In Now
Expect US stocks to get an additional boost on a rotation into cyclical, economically sensitive industries that have lagged amid the US-Iran war.
12 Best Revenue Growth Stocks to Buy According to Wall Street Analysts
On May 22, Reuters reported that high-flying US stocks could face more ups and downs in the final days of a blowout corporate earnings season.
10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts
On May 13, Reuters reported that Morgan Stanley increased its annual target for the benchmark S&P 500 index.